open access

Vol 15, No 1 (2020)
Review Papers
Get Citation

Modern therapy of acute coronary syndromes based on prasugrel — available to Polish patients

Beata Wożakowska-Kapłon
Folia Cardiologica 2020;15(1):56-60.

open access

Vol 15, No 1 (2020)
Review Papers

Abstract

Patients with acute coronary syndromes undergoing primary percutaneous coronary intervention should receive dual-antiplatelet therapy, a combination of acetylsalicylic acid and a P2Y12 inhibitor. The preferred P2Y12 inhibitors are prasugrel or ticagrelor. These drugs have a more rapid onset of action, greater potency, and are superior to clopidogrel in terms of clinical outcomes. Prasugrel is contraindicated in patients with previous stroke/transient ischaemic attack, and its use is generally not recommended in patients aged > 75 years or in patients with lower body weight (< 60 kg) as it has not been associated with net clinical benefit in these subsets. If prasugrel is used in these patients after benefits and risks have been weighted, a reduced maintenance dose (5 mg) is recommended.

Ticagrelor may cause transient dyspnoea at the onset of therapy, which rarely leads to permanent discontinuation. Neither prasugrel nor ticagrelor should be used in patients with a previous haemorrhagic stroke, in patients on oral anticoagulants, or in patients with moderate-to-severe liver disease. When neither of these agents is available (or if they are contraindicated), clopidogrel should be given instead. In most cases, Polish patients have been deprived of modern treatment strategies using potent P2Y12 inhibitors for economic reasons, but generic prasugrel is currently available.

Abstract

Patients with acute coronary syndromes undergoing primary percutaneous coronary intervention should receive dual-antiplatelet therapy, a combination of acetylsalicylic acid and a P2Y12 inhibitor. The preferred P2Y12 inhibitors are prasugrel or ticagrelor. These drugs have a more rapid onset of action, greater potency, and are superior to clopidogrel in terms of clinical outcomes. Prasugrel is contraindicated in patients with previous stroke/transient ischaemic attack, and its use is generally not recommended in patients aged > 75 years or in patients with lower body weight (< 60 kg) as it has not been associated with net clinical benefit in these subsets. If prasugrel is used in these patients after benefits and risks have been weighted, a reduced maintenance dose (5 mg) is recommended.

Ticagrelor may cause transient dyspnoea at the onset of therapy, which rarely leads to permanent discontinuation. Neither prasugrel nor ticagrelor should be used in patients with a previous haemorrhagic stroke, in patients on oral anticoagulants, or in patients with moderate-to-severe liver disease. When neither of these agents is available (or if they are contraindicated), clopidogrel should be given instead. In most cases, Polish patients have been deprived of modern treatment strategies using potent P2Y12 inhibitors for economic reasons, but generic prasugrel is currently available.

Get Citation

Keywords

acute coronary syndrome, antiplatelet agents, prasugrel

About this article
Title

Modern therapy of acute coronary syndromes based on prasugrel — available to Polish patients

Journal

Folia Cardiologica

Issue

Vol 15, No 1 (2020)

Pages

56-60

Bibliographic record

Folia Cardiologica 2020;15(1):56-60.

Keywords

acute coronary syndrome
antiplatelet agents
prasugrel

Authors

Beata Wożakowska-Kapłon

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl